Enrolling by invitationPhase 4NCT05777993
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
Studying Hemolytic anemia due to red cell pyruvate kinase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Intervention
- Mitapivat(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (4)
- McMaster Centre for Transfusion Medicine McMaster University, Hamilton, Ontario, Canada
- Tohoku University Hospital, Sendai, Miyagi, Japan
- Kyoto Katsura Hospital, Kyoto, Japan
- Toho University - Omori Medical Center, Ōta-ku, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05777993 on ClinicalTrials.gov